NPGS offers a good alternative to trabeculectomy

Article

Non-penetrating glaucoma surgery (NPGS) is a safe and effective filtering procedure and could offer an alternative to trabeculectomy in patients with open angle glaucoma, according to Dr Aslan and colleagues from Ege University School of Medicine, Turkey.

Non-penetrating glaucoma surgery (NPGS) is a safe and effective filtering procedure and could offer an alternative to trabeculectomy in patients with open angle glaucoma, according to Dr Aslan and colleagues from Ege University School of Medicine, Turkey.

A total of 112 patients (124 eyes) with uncontrolled primary and secondary open angle glaucoma, were enrolled to take part in the study. The patients were divided into four treatment groups: viscocanalostomy (56 eyes), deep sclerectomy with non-absorbable T-Flux implant (33 eyes), deep sclerectomy with reticulated hyaluronic acid implant (SKGEL) (14 eyes) and deep sclerectomy with collagen implant (DSCI).

Mean intraocular pressure (IOP) decreased from 25.5±7.6 mmHg at baseline to 15.9±4.6 mmHg at six months, to 17.0±5.6 mmHg at one year, 16.7±4.1 mmHg at year three and 15.5±2.5 mmHg at year five in all patients. No significant difference in success rate was found between the various techniques.

The investigators suggest that NPGS is not only safe and effective, but may be a good alternative to trabeculectomy in patients with uncontrolled open angle glaucoma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.